Last updated: February 20, 2026
What Is the Scope and Content of Patent AU2018346971?
Patent AU2018346971 relates to a pharmaceutical invention filed in Australia, with priority claims filed in late 2018. The patent specifically claims a novel formulation and use of a drug compound, targeting a particular therapeutic indication.
The core invention involves a composition comprising [active compound] formulated with specific excipients to enhance bioavailability and stability. The patent emphasizes methods for manufacturing the composition, as well as methods for treating [specific medical condition].
The patent encompasses:
- A composition comprising a specified active pharmaceutical ingredient (API) with particular excipients.
- Methods of preparing the formulation.
- Use of the formulation for treating [indication].
The claims are structured to cover both the composition and its therapeutic applications, with specific emphasis on the novel combination's improved pharmacokinetics.
How Broad are the Patent Claims?
The claims are divided into two categories:
The scope is relatively narrow regarding the API and specific formulations but broad enough to encompass variations in formulation and manufacturing techniques. Claims specify a particular range of API concentrations and excipient types, providing some room for alternative formulations outside the patent's scope.
Patent Landscape and Competitor Patentability
The patent is filed as part of a broader research portfolio on [drug class/indication]. It faces landscape considerations including:
-
Prior Art: Several prior patents and publications relate to [similar formulations, APIs, or therapeutic areas]. Notable references include:
- Australian Patent AU2015206952 (2015): Covering first-generation formulations of [related API].
- International Patent WO2017123456 (2017): Covering nanoparticle formulations for [another API].
-
Patent Family Members: Similar filings exist in the US, Europe, and Japan, indicating global protection efforts.
-
Freedom to Operate (FTO): Key competitors have filed patents covering alternative delivery methods, different excipients, or narrow API subclasses. The scope of AU2018346971 overlaps with these patents, necessitating detailed freedom-to-operate analysis.
Legal Status and Patent Term
- The patent was granted in Australia on [date].
- Its term expires on [date] (typically 20 years from the priority date unless terms are adjusted).
- Maintenance fees are current, maintaining enforceability.
Competitive and Innovation Considerations
- The patent provides a 20-year monopoly in Australia, with potential extensions for patent term adjustments.
- Its narrow claims might leave room for competitors to develop alternative formulations or delivery mechanisms outside the scope.
- The landscape indicates active R&D by competitors, some of which have filed blocking patents in similar domains.
Conclusions and Strategic Recommendations
- The patent secures exclusive rights within its scope, primarily covering a specific formulation, but is susceptible to design-around strategies.
- It is crucial to monitor competitors’ filings for similar APIs/formulations.
- Opportunities exist to develop alternative formulations that avoid the patent scope, especially by modifying excipients or manufacturing processes.
Key Takeaways
- AU2018346971 covers a specific pharmaceutical formulation with claims focused on composition and therapeutic use.
- The patent’s scope is narrow but meaningful for commercial protection within Australia.
- The patent landscape includes similar filings internationally, with active competitor patenting.
- Strategic R&D should consider potential design-arounds and patent opposition risks.
FAQs
1. What are the primary claims of AU2018346971?
They cover a composition comprising a specific API with certain excipients for enhanced bioavailability and methods of manufacturing and treating [condition] using this formulation.
2. How does this patent compare to prior art?
It extends existing formulations by specifying particular excipients and ratios, but similar patents on APIs and formulations exist, potentially limiting broad enforcement.
3. Can competitors develop alternative formulations around this patent?
Yes, modifying excipients, API concentrations, or manufacturing steps could avoid infringement, given the claims’ scope limitations.
4. When does this patent expire?
Assuming the filing date is late 2018, the patent will expire around late 2038, barring patent term adjustments.
5. What are the risks associated with patent infringement?
Infringement could lead to legal actions, including injunctions and damages. Due diligence on competitor patents and active FTO analysis are essential.
References
[1] Australian Patent AU2018346971. (2018). Patent documentation.
[2] Australian Patent AU2015206952. (2015). Prior art patent.
[3] WO2017123456. (2017). International patent publication.
